Published in Eur J Cancer on July 30, 2008
Hurdles in anticancer drug development from a regulatory perspective. Nat Rev Clin Oncol (2012) 0.90
Rare diseases: what's next? Lancet (2008) 3.06
Smoking in Italy 2005-2006: effects of a comprehensive National Tobacco Regulation. Prev Med (2007) 2.61
Orphan drug development is not taking off. Br J Clin Pharmacol (2009) 2.27
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res (2010) 2.21
Which domains should be included in a cancer pain classification system? Analyses of longitudinal data. Pain (2012) 2.07
Orphan drug development is progressing too slowly. Br J Clin Pharmacol (2006) 1.79
Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Rheum (2009) 1.71
Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol (2012) 1.68
Disappointing biotech. BMJ (2005) 1.66
Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis. Lancet Infect Dis (2009) 1.55
Anything new in EU pharmacovigilance? Eur J Clin Pharmacol (2011) 1.53
Paget's disease of bone: a review. Rheumatol Int (2008) 1.50
Thrombocytosis in systemic lupus erythematosus: a possible clue to autosplenectomy? J Rheumatol (2007) 1.45
Mild depression in general practice: is the automatism of antidepressant prescribing an evidence-based approach? Acta Psychiatr Scand (2006) 1.42
A prospective study on survival in cancer patients with and without venous thromboembolism. Intern Emerg Med (2013) 1.42
Increased risk of myocardial infarction with dabigatran: fact or fiction? J Cardiovasc Med (Hagerstown) (2014) 1.42
The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine (2012) 1.41
Varying and "atypical" indications for atypical antipsychotics. Psychopharmacology (Berl) (2003) 1.40
Metabolic syndrome and health-related quality of life: does psychological well-being matter? Ann Epidemiol (2008) 1.40
Clinical predictors in chronic articular adult-onset Still's disease: comment on the article by Ichida et al. Arthritis Care Res (Hoboken) (2014) 1.39
Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol (2012) 1.39
Italy must invest more in science and technology. Nature (2008) 1.38
Central nervous system involvement in Sjögren's syndrome: unusual, but not unremarkable--clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology (Oxford) (2010) 1.34
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol (2007) 1.34
Prevalence, incidence and types of mild anemia in the elderly: the "Health and Anemia" population-based study. Haematologica (2010) 1.28
Adult-onset Still's disease. Rheumatol Int (2009) 1.27
Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem (2003) 1.24
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis (2006) 1.16
Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the "Health and Anemia" study. PLoS One (2008) 1.15
Body weight, gender and response to TNF-α blockers in axial spondyloarthritis. Rheumatology (Oxford) (2014) 1.14
Association of mild anemia with hospitalization and mortality in the elderly: the Health and Anemia population-based study. Haematologica (2008) 1.14
Quality of life in breast and colon cancer long-term survivors: an assessment with the EORTC QLQ-C30 and SF-36 questionnaires. Tumori (2002) 1.11
"SAPHO syndrome and infections". Autoimmun Rev (2008) 1.08
Autosplenectomy and antiphospholipid antibodies in systemic lupus erythematosus: A pathogenetic relationship? Semin Arthritis Rheum (2003) 1.06
Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum (2009) 1.06
A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res Ther (2011) 1.04
Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford) (2011) 1.04
Epilepsy and quality of life in adults: a review of instruments. Epilepsy Res (2005) 1.03
Development and validation of the short version of the Psychological General Well-Being Index (PGWB-S). Health Qual Life Outcomes (2006) 1.03
HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet Genomics (2006) 1.02
Physician-delivered advice to quit smoking among Italian smokers. Am J Prev Med (2008) 1.02
Construct validity of the Short Form-36 Health Survey and its relationship with BMI in obese outpatients. Obesity (Silver Spring) (2006) 1.02
Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res (2008) 1.00
The metabolic syndrome in treatment-seeking obese persons. Metabolism (2004) 1.00
Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice. J Clin Oncol (2011) 1.00
Enhancing the rational use of new medicines across European health care systems. Eur J Clin Pharmacol (2008) 0.99
Influenza vaccine in healthy children: a meta-analysis. Vaccine (2005) 0.99
Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. Arthritis Rheum (2009) 0.98
Reconsidering the Declaration of Helsinki. Lancet (2013) 0.98
Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease. Eur J Clin Pharmacol (2008) 0.98
Clinical and psychological correlates of health-related quality of life in obese patients. Health Qual Life Outcomes (2010) 0.97
Networking properties of cyclodextrin-based cross-linked polymers probed by inelastic light-scattering experiments. J Phys Chem B (2012) 0.96
Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. Clin J Pain (2011) 0.95
Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. Int Clin Psychopharmacol (2006) 0.95
Which variables are associated with pain intensity and treatment response in advanced cancer patients?--Implications for a future classification system for cancer pain. Eur J Pain (2010) 0.94
Prevalence of smoking and attitude towards smoking regulation in Italy, 2004. Eur J Cancer Prev (2006) 0.94
Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. Rheumatology (Oxford) (2010) 0.94
Drug distribution and expenditure: the issue of epoetin in Italy. Eur J Public Health (2003) 0.93
Adaptive immunity, inflammation, and cardiovascular complications in type 1 and type 2 diabetes mellitus. J Diabetes Res (2013) 0.92
Endothelial nitric oxide synthase gene polymorphisms in Behçet's disease. J Rheumatol (2002) 0.91
Effect of cross-linking properties on the vibrational dynamics of cyclodextrins-based polymers: an experimental-numerical study. J Phys Chem B (2012) 0.91
Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech (2011) 0.90
Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm (2009) 0.90
Post-traumatic stress disorder. N Engl J Med (2002) 0.90
Fluoxetine dose and outcome in antidepressant drug trials. Eur J Clin Pharmacol (2002) 0.90
Fatal myocarditis in adult-onset Still disease with diffuse intravascular coagulation. Rheumatol Int (2008) 0.90
Use of pharmacotherapy for smoking cessation in Italy. Arch Intern Med (2009) 0.90
A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. Arch Intern Med (2007) 0.89
Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology (Oxford) (2009) 0.88
Abnormalities of left ventricular function in asymptomatic patients with systemic sclerosis using Doppler measures of myocardial strain. J Am Soc Echocardiogr (2008) 0.87
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res (2014) 0.87
Elderly-onset gout: a review. Rheumatol Int (2007) 0.87
Satisfaction surveys: do we really need new questionnaires? Int J Qual Health Care (2005) 0.87
Smoking in Italy, 2002. Tumori (2003) 0.87
Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. J Med Chem (2009) 0.87
Nanosponge formulations as oxygen delivery systems. Int J Pharm (2010) 0.86
The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum (2011) 0.86
Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown. Eur Heart J (2012) 0.86
CXCR4 pos circulating progenitor cells coexpressing monocytic and endothelial markers correlating with fibrotic clinical features are present in the peripheral blood of patients affected by systemic sclerosis. Haematologica (2008) 0.86
Withdrawal of 'Xigris' from the market: old and new lessons. J Epidemiol Community Health (2012) 0.86
Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. Eur J Pharm Sci (2012) 0.86
Pre-market clinical evaluations of innovative high-risk medical devices in Europe. Int J Technol Assess Health Care (2012) 0.86
Catalytic properties of catechol 1,2-dioxygenase from Acinetobacter radioresistens S13 immobilized on nanosponges. Dalton Trans (2009) 0.85
Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers. Tumori (2014) 0.85
Infections, immunity and atherosclerosis: pathogenic mechanisms and unsolved questions. Int J Cardiol (2012) 0.85
Discussing study limitations in reports of biomedical studies- the need for more transparency. Health Qual Life Outcomes (2012) 0.85
Digital clubbing or digital "pseudoclubbing" in systemic sclerosis. J Clin Rheumatol (2006) 0.85
Drug sales in four European countries still differ. BMJ (2003) 0.85
Flaws in animal studies exploring statins and impact on meta-analysis. Eur J Clin Invest (2014) 0.84
Late onset systemic lupus erythematosus: no substantial differences using different cut-off ages. Rheumatol Int (2006) 0.84
Preparation and in vitro evaluation of the antiviral activity of the Acyclovir complex of a beta-cyclodextrin/poly(amidoamine) copolymer. J Control Release (2007) 0.84
Smoking in Italian women and men, 2001. Tumori (2002) 0.84
Regulatory policies on medicines for psychiatric disorders: is Europe on target? Br J Psychiatry (2007) 0.84
Thrombolysis or nothing for acute myocardial infarction? It's all the same! Br J Clin Pharmacol (2008) 0.84
Expert conference on cancer pain assessment and classification--the need for international consensus: working proposals on international standards. BMJ Support Palliat Care (2011) 0.83